17 June 2021 | News
AYUSH-64 was repurposed after scientific evidence generated from seven clinical studies across India
Sri Sri Tattva has introduced the AYUSH-64 tablets, which is been recognised by the Ministry of Ayush for being effective in the treatment of mild to moderate COVID-19 patients. It has obtained technology transfer from National Research & Development Corporation and will manufacture and distribute it nationally and internationally.
AYUSH-64 tablets were launched in the presence of Vaidya Rajesh Kotecha, Secretary, Ministry of Ayush, Arvind Varchaswi, MD, Sri Sri Tattva, Vaidya Devendra Triguna, President, All India Ayurveda Congress, Bhushan Patwardhan, Former Vice-Chairman, University Grants Commission (UGC), Dr N Srikanth, Director General, The Central Council for Research in Ayurvedic Sciences (CCRAS), Rajiv Vasudevan, Founder AyurVAID Hospitals and Vikas Chauhan, Co-founder, 1 mg.
AYUSH-64 was repurposed after scientific evidence generated from seven clinical studies across India. It has been identified as a potential adjunct to standard care in the management of asymptomatic, mild and moderate COVID-19 to improve the clinical recovery and quality of life through robust clinical trials conducted in the country. The in-silico study done on AYUSH-64 showed that about 35 out of 36 of its Phyto-constituents have a high binding affinity against the COVID-19 virus.
Varchaswi said, “We have entered into a strategic partnership with 1 mg, to reach out to more people in need.”
Kotecha said, “AYUSH-64 is not an immunomodulator, it is a drug repurposed for the treatment of COVID-19. The ingredients have immunomodulatory effects, but the study is done for the use of AYUSH-64 as a treatment in COVID-19 as an add on or as stand-alone. Docking studies were carried out for AYUSH-64 at NIN, ICMR and IIT, BHU. Preclinical studies were also carried out at THSTI and DBT Institute.”